ArticleDiscover oncology2026
A new oxidative stress-related lncRNA signature predicts the prognosis of colorectal cancer patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Colorectal cancer (CRC) is a common malignant tumor of the digestive system with a high incidence. Increasing evidence suggests that oxidative stress (OS) generates high levels of reactive oxygen species (ROS) and free radicals and is a significant factor in aging and disease. However, the predictive value of OS-related long non-coding RNA (lncRNA) in CRC is unclear. We constructed a survival predictor based on OS-related lncRNAs obtained from the Cancer Genome Atlas (TCGA-COAD) to predict the prognosis of patients with CRC. The feature includes four lncRNAs, LINC02474, AL513550.1, SNHG16, and AL161729.4. The OS-related lncRNA signature demonstrated superior predictive accuracy to conventional clinicopathological parameters, with an area under the receiver operating characteristic curve (AUC) of 0.768, indicating its potential as a robust prognostic biomarker. Furthermore, the nomogram based on risk scores and clinicopathological variables (age, gender, grade, stage, M stage, and N stage) showed strong predictive performance. High-risk patients were found to be more sensitive to treatment drugs ABT.263, AZD.0530, gefitinib, imatinib, PAC.1, and shikonin. The predictive model we constructed can independently predict the prognosis of patients with CRC. Further experimental validation and mechanistic studies are warranted to elucidate the precise role of OS-related lncRNAs in CRC pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.